ML-11 Tirabrutinib treatment for recurrent or refractory PCNSL

Since 2020, tirabrutinib which is a Bruton’s tyrosine kinase (BTK) inhibitor has been available for recurrent or refractory PCNSL cases. The number of studies reporting efficiency and adverse effect of tirabrutinib treatment for recurrent or refractory PCNSL has been limited yet. In this study, we i...

Descripción completa

Detalles Bibliográficos
Autores principales: Ohka, Fumiharu, Yamaguchi, Junya, Motomura, Kazuya, Aoki, Kosuke, Nishikawa, Tomohide, Kibe, Yuji, Yamazaki, Shintaro, Natsume, Atsushi, Saito, Ryuta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Supplement Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648252/
http://dx.doi.org/10.1093/noajnl/vdab159.090

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648252/
http://dx.doi.org/10.1093/noajnl/vdab159.090

Ejemplares similares